# A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

> **NCT04856631** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 88 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Cancer

## Interventions

- **DRUG:** Toripalimab Injection
- **DRUG:** Cetuximab Solution for infusion

## Key facts

- **NCT ID:** NCT04856631
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-06
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2022-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04856631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04856631, "A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04856631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*